FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4235870760> ?p ?o ?g. }

• W4235870760 endingPage "S41" @default.
• W4235870760 startingPage "S40" @default.
• W4235870760 abstract "The benefit of adding androgen deprivation therapy (ADT) to dose- escalated radiation therapy (RT) for men with intermediate-risk prostate cancer is unclear, therefore, we assessed the impact of adding ADT to dose- escalated RT on PSA disease-free survival (bDFS). Three groups of men treated with IMRT or 3D conformal RT from 1993-2008 for prostate cancer with doses ranging from 75.6-78 Gy were identified: (1) 327 intermediate-risk patients (NCCN classification) treated with RT alone, (2) 218 intermediate-risk patients treated with RT and <6 months of ADT, and (3) 274 low-risk patients treated with definitive RT. Median follow-up was 58 months. Recursive partitioning analysis using Gleason Score (GS), T-Stage, and pretreatment PSA was applied to the intermediate-risk patients treated with RT alone to identify prognostic groups based on risk of PSA recurrence (Phoenix definition). All intermediate-risk patients were then stratified by these prognostic subgroups. Intermediate-risk patients treated with RT alone were compared to intermediate-risk patients treated with RT and ADT and to low-risk patients treated with RT alone. Kaplan-Meier method was used to estimate the 5 year bDFS. Based on recursive partitioning analysis of 5 year bDFS, intermediate-risk patients treated with RT alone were classified into 3 prognostic groups: (1) 188 favorable patients with T1b-T2b GS 6 or T1b-c GS 3+4; (2) 71 marginal patients with T2a-b GS 3+4; and (3) 68 unfavorable patients with T2c or GS 4+3 disease. Associated hazard ratios (HR) for recurrence were 1.0, 2.1, and 4.5, respectively. PSA was not found to be a major contributing factor in this analysis. When intermediate-risk patients treated with RT alone were compared to intermediate-risk patients treated with RT and ADT, the greatest benefit from ADT was seen for the unfavorable intermediate-risk patients (bDFS 74% vs. 94%; HR 0.234; p = .005). Favorable intermediate-risk patients had no significant benefit from the addition of ADT to RT (bDFS 94% vs. 95%; p = 0.85), and bDFS for favorable intermediate-risk patients treated with RT alone approached the bDFS for low-risk patients treated with RT alone (98%). In the marginal prognosis subgroup, 5 year bDFS was 91% without ADT and 100% with ADT, p = .07. Patients with favorable intermediate- risk prostate cancer did not benefit from the addition of ADT to dose- escalated RT and their bDFS was nearly as good as patients with low-risk disease. However, in patients with GS 4+3 and higher volume disease, the addition of ADT to dose- escalated RT did improve bDFS. Since randomized trials addressing this issue in the high dose era are lacking, consideration should be given to a personalized approach, taking into account tumor characteristics and patient comorbidities." @default.
• W4235870760 created "2022-05-12" @default.
• W4235870760 creator A5000208935 @default.
• W4235870760 creator A5001478135 @default.
• W4235870760 creator A5022981230 @default.
• W4235870760 creator A5023408462 @default.
• W4235870760 creator A5037131932 @default.
• W4235870760 creator A5047785180 @default.
• W4235870760 creator A5051028960 @default.
• W4235870760 creator A5059107678 @default.
• W4235870760 creator A5075621917 @default.
• W4235870760 creator A5089574427 @default.
• W4235870760 date "2011-10-01" @default.
• W4235870760 modified "2023-09-25" @default.
• W4235870760 title "Is Androgen Deprivation Therapy Necessary in Intermediate Risk Prostate Cancer Patients Treated in the Dose Escalation Era?" @default.
• W4235870760 doi "https://doi.org/10.1016/j.ijrobp.2011.06.083" @default.
• W4235870760 hasPublicationYear "2011" @default.
• W4235870760 type Work @default.
• W4235870760 citedByCount "0" @default.
• W4235870760 crossrefType "journal-article" @default.
• W4235870760 hasAuthorship W4235870760A5000208935 @default.
• W4235870760 hasAuthorship W4235870760A5001478135 @default.
• W4235870760 hasAuthorship W4235870760A5022981230 @default.
• W4235870760 hasAuthorship W4235870760A5023408462 @default.
• W4235870760 hasAuthorship W4235870760A5037131932 @default.
• W4235870760 hasAuthorship W4235870760A5047785180 @default.
• W4235870760 hasAuthorship W4235870760A5051028960 @default.
• W4235870760 hasAuthorship W4235870760A5059107678 @default.
• W4235870760 hasAuthorship W4235870760A5075621917 @default.
• W4235870760 hasAuthorship W4235870760A5089574427 @default.
• W4235870760 hasBestOaLocation W42358707601 @default.
• W4235870760 hasConcept C121608353 @default.
• W4235870760 hasConcept C126322002 @default.
• W4235870760 hasConcept C126894567 @default.
• W4235870760 hasConcept C143998085 @default.
• W4235870760 hasConcept C207103383 @default.
• W4235870760 hasConcept C2776235491 @default.
• W4235870760 hasConcept C2777008409 @default.
• W4235870760 hasConcept C2777899217 @default.
• W4235870760 hasConcept C2779466945 @default.
• W4235870760 hasConcept C2779668873 @default.
• W4235870760 hasConcept C2780192828 @default.
• W4235870760 hasConcept C44249647 @default.
• W4235870760 hasConcept C50382708 @default.
• W4235870760 hasConcept C509974204 @default.
• W4235870760 hasConcept C71924100 @default.
• W4235870760 hasConceptScore W4235870760C121608353 @default.
• W4235870760 hasConceptScore W4235870760C126322002 @default.
• W4235870760 hasConceptScore W4235870760C126894567 @default.
• W4235870760 hasConceptScore W4235870760C143998085 @default.
• W4235870760 hasConceptScore W4235870760C207103383 @default.
• W4235870760 hasConceptScore W4235870760C2776235491 @default.
• W4235870760 hasConceptScore W4235870760C2777008409 @default.
• W4235870760 hasConceptScore W4235870760C2777899217 @default.
• W4235870760 hasConceptScore W4235870760C2779466945 @default.
• W4235870760 hasConceptScore W4235870760C2779668873 @default.
• W4235870760 hasConceptScore W4235870760C2780192828 @default.
• W4235870760 hasConceptScore W4235870760C44249647 @default.
• W4235870760 hasConceptScore W4235870760C50382708 @default.
• W4235870760 hasConceptScore W4235870760C509974204 @default.
• W4235870760 hasConceptScore W4235870760C71924100 @default.
• W4235870760 hasIssue "2" @default.
• W4235870760 hasLocation W42358707601 @default.
• W4235870760 hasOpenAccess W4235870760 @default.
• W4235870760 hasPrimaryLocation W42358707601 @default.
• W4235870760 hasRelatedWork W1515906819 @default.
• W4235870760 hasRelatedWork W1760780539 @default.
• W4235870760 hasRelatedWork W1979955543 @default.
• W4235870760 hasRelatedWork W1992247710 @default.
• W4235870760 hasRelatedWork W2042143271 @default.
• W4235870760 hasRelatedWork W2192988598 @default.
• W4235870760 hasRelatedWork W2466734156 @default.
• W4235870760 hasRelatedWork W2529939135 @default.
• W4235870760 hasRelatedWork W2898154622 @default.
• W4235870760 hasRelatedWork W4307585143 @default.
• W4235870760 hasVolume "81" @default.
• W4235870760 isParatext "false" @default.
• W4235870760 isRetracted "false" @default.
• W4235870760 workType "article" @default.